RxDoctor Payments Data

Kerobin Lapawon, APRN

Psychiatric/Mental Health · Miami, FLNPI 1255067369

Payments from drug & device makers

$5,460in general payments, 2019–2025

Across 261 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$704
  • AbbVie$689
  • Otsuka America Pharmaceutical, Inc.$631
  • Teva Pharmaceuticals USA, Inc.$561
  • Vanda Pharmaceuticals Inc.$410
  • Axsome Therapeutics, Inc.$387
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$5,34998%
  • Education$1112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,460 in reported general payments places this provider in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$17,581
Medicare patients
33
Services billed
221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl30$45,964
RexultiBrexpiprazole12$17,461
AuvelityDextromethorphan Hbr/Bupropion12$13,563
Lurasidone Hcl40$11,240
Paliperidone ErPaliperidone29$4,606
Ziprasidone Hcl46$3,441
Quetiapine Fumarate156$2,721
Hydroxyzine Hcl77$1,924
Aripiprazole56$1,784
Bupropion XlBupropion Hcl78$1,567
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine29$1,346
Clonazepam125$1,179
Alprazolam63$1,172
Prazosin Hcl70$966
Olanzapine41$929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$689$45,96430 claims
Otsuka America Pharmaceutical, Inc.Rexulti$631$17,46112 claims
Axsome Therapeutics, Inc.Auvelity$387$13,56312 claims
Almatica Pharma LLCSertraline Hcl$119$35659 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →